Showing 1901-1910 of 5696 results for "".
- Nicox Outlines Future Development and Partnering Plans for NCX 470https://modernod.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. “Our market research&nbs
- Medicontur Launches Bi-Flex Elon Nondiffractive EDOF IOLhttps://modernod.com/news/medicontur-launches-bi-flex-elon-nondiffractive-edof-iol/2481224/Medicontur announced the launch of the Bi-Flex Elon Nondiffractive EDOF IOL. The Elon, which was launched on September 6, features proprietary Wavefront Linking technology that is designed to create a true elongated focus with minimal optical disturbances. This non-d
- CooperVision Adds SynergEyes to Expand Specialty Contact Lens Adoption in North Americahttps://modernod.com/news/coopervision-adds-synergeyes-to-expand-specialty-contact-lens-adoption-in-north-america/2481220/Deepening its commitment to expand specialty contact lens adoption in North America and worldwide, CooperVision has added
- Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol for the Treatment of Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-fda-acceptance-of-the-new-drug-application-for-cyclasol-for-the-treatment-of-dry-eye-disease/2481186/Novaliq announced that the FDA has accepted the new drug application (NDA) for CyclASol (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED). The agency completed the filing revi
- Harrow Sells Non-Ophthalmic Compounding Businesshttps://modernod.com/news/harrow-sells-non-ophthalmic-compounding-business/2481162/Harrow announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation. Financial terms of the deal were not disclosed. Revelation purchased the assets of Harrow’s non‑ophthalmic c
- NovaSight Announces FDA 510(K) Clearance of CureSight Digital Therapy for Amblyopiahttps://modernod.com/news/novasight-announces-fda-510k-clearance-of-curesight-digital-therapy-for-amblyopia/2481148/NovaSight announced that the FDA has cleared CureSight, a digital therapy device for amblyopia (lazy eye). CureSight is an eye-tracking-based system aimed for improving visual acuity and stereo acuity by training the visual system to use both eyes simultaneously. The ground-breaking cle
- Haag-Streit to Host a Series of Educational Webinars as Part of its Biometry Focus Month in Novemberhttps://modernod.com/news/haag-streit-to-host-a-series-of-educational-webinars-as-part-of-its-biometry-focus-month-in-november/2481139/Haag-Streit will host a variety of educational webinars as part of its Biometry Focus Month in November. This series of webinars will be delivered by a distinguished faculty consisting of notable key opinion leaders, complemented by Haag-Streit biometry product specialists. Hosted on Zo
- Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitishttps://modernod.com/news/tarsus-launches-look-at-the-lids-campaign-to-encourage-eye-care-professionals-to-identify-and-diagnose-demodex-blepharitis/2481133/Tarsus Pharmaceuticals announced the launch of the “Look at the Lids” disease education campaign for Demodex blepharitis, a common lid margin disease that can negatively impact patients’ daily activities and eyelid health. The novel campaign is designed to encourage ey
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-trial-of-eyp-1901-for-the-treatment-of-non-proliferative-diabetic-retinopathy/2481131/EyePoint Pharmaceuticals announced that the first patient has been dosed in the phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting non-proliferative diabetic retinopathy (NPDR).
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica